Journal :
Contraception / Tandfonline (2024) · 2024
Evaluates how hormonal contraceptives reduce symptom severity and bleeding in women with heavy menstrual bleeding (HMB), with tradeoffs in side-effect profiles.
Journal :
JAMA (Feb 2025) · 2025
This work assesses VTE risk among modern hormonal contraceptives, showing that estrogen dose and progestin choice meaningfully influence the absolute and relative VTE risk.
Journal :
The BMJ (Jan 2025) · 2025
Registry analysis: slight increased risk of meningioma after >5 years continuous use of desogestrel 75 µg; no risk signal for levonorgestrel.
Journal :
The BMJ (Mar 2024) · 2024
French nationwide data: prolonged use of certain high-dose progestogens is associated with increased intracranial meningioma risk; no increased risk observed with levonorgestrel IUD.
Journal :
The BMJ (Sep 2023) · 2023
Nationwide Danish cohort: combining NSAIDs with certain hormonal contraceptives significantly raises VTE risk compared to low-risk contraceptives or none; suggests careful concomitant prescribing.
Journal :
PLOS Medicine (Mar 2023) · 2023
Case-control + meta-analysis: current/recent use of any hormonal contraceptive (combined or progestagen-only) shows ~20-30 % relative increase in breast cancer risk; absolute risk low and decreases after stopping.
Drag